Anti-Hepatitis B Surface Antibody (Anti-HBsAb) in a Representative Population of Ozuoba in Rivers State, Nigeria by Agbagwa, O.E. et al.
 Journal of Therapy and Management in HIV Infection, 2018, 6, 9-15 9 
 
 E-ISSN: 2309-0529/18  © 2018 Synergy Publishers 
Anti-Hepatitis B Surface Antibody (Anti-HBsAb) in a 
Representative Population of Ozuoba in Rivers State, Nigeria 
O.E. Agbagwa, T.F. Simon and I.O. Okonko* 
Medical Microbiology Unit, Department of Microbiology, University of Port Harcourt. P.M.B 5323, Choba, 
East-West Road Port Harcourt, Rivers State, 500102, Nigeria 
Abstract: Background: Hepatitis B infection is a foremost worldwide health issue of public health significance and chief 
origin of chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC). There are vaccines available for hepatitis B 
infection which can be used for prevention before infection. In an effort to prevent and control HBV, the Nigeria 
Government in 2004 made HBV vaccine as part of national immunization programme. This definitely is an essential 
procedure to minimize the occurrence of HBV in many countries. Thus, our study was designed to investigate the 
seroprevalence of hepatitis B surface antibody (HBsAb) in a representative population of Ozuoba in Rivers State, Nigeria 
following the incorporation of HBV vaccine into NPI schedule.  
Methods: Ninety (90) blood samples were obtained from a male and female population of Ozuoba community in Rivers 
State, Nigeria. Questionnaires were distributed to obtain demographic profile of participants. ELISA (DIA.PRO Diagnostic 
Bioprobes, Milano-Italy) was employed for the qualitative and quantitative evaluation of HBsAb in sera and plasma of 
representative population of Ozuoba in Rivers State, Nigeria. The serological evaluation and result interpretation were 
carried out as stipulated by the kit’s manufacturers. We engaged Fisher's exact test and Chi-square test to estimate 
variances amid groups at p < 0.05 significance.  
Results: Of the 90 participants evaluated, nine tested seropositive for HBsAb giving a general prevalence of 10.0% and a 
seronegativity of 90.0%. The sex-related prevalence was males (7.1%) and females (12.5%). Sex and age had no effect 
in hepatitis B surface antibody (p-value >0.05). The age-specific prevalence was 7.7% for age group 13-19 years, 10.2% 
for 20-35 years of age and 10.7% for 36 years and above.  
Conclusion: This study revealed that the presence of HBsAb was low (10.0%). Our outcomes indicted that seropositivity 
and seronegativity of HBsAb have no significant relationship with age and sex. It further showed that 90.0% were HBsAb 
seronegative and hence, more susceptible to HBV infection. Vaccination programme must be strengthened further to 
grasp those continuing at highest risk. 
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1. INTRODUCTION  
Infection caused by HBV is a foremost worldwide 
health issue of public health significance and chief 
origin of chronic hepatitis, cirrhosis and hepatocellular 
carcinoma (HCC) [1-4]. In Nigeria HBV is 
hyperendemic [5, 6]. Chronic HBV infection is mainly 
acquired in infantile through the horizontal mode of 
transmission since the majority of children cannot clear 
the virus from their body [5]. Approximately two billion 
persons were estimated to have had a serological 
indication of present or past HBV infection [1, 7]. Over 
360 million persons are HBV chronic carriers [1, 7] and 
it is hyperendemic (i.e. >8% of the population infected) 
in Sub-Sahara Africa (SSA) [6]. As stated, 15-40% of 
HBV positive persons would progress to cirrhosis, liver 
failure or HCC [1, 8-9] and annually, about half a million 
to 1.2 million persons die owing to HBV [1, 10-11]. The 
worldwide disease burden of HBV is considerable 
owing to the elevated HBV-connected illness and death  
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[1, 9], however, it varies depending on the geographic 
area [12].  
Reports have shown that in countries such as 
United States, Canada and Western Europe are low 
prevalence areas of HBV which ranges from <2% to 2 
to 7% in intermediate-prevalence areas (e.g., 
Mediterranean countries, Japan, Central Asia, Middle 
East, and parts of South America) to ≥8% in high-
prevalence areas (e.g., Western Africa, South Sudan) 
[12-15]. In 90% perinatally acquired infection can 
progress from acute to complicated HBV infection [16]. 
20 to 50% for infections between the age of one and 
five years there is 20 to 50% increase or progression 
HBV [17-18], and less than 5% for adult-acquired 
infection [17]. 
“WHO called on all nations to include HBV vaccine 
in the National Program on Immunisation (NPI) 
schedules since 1991.” World Health Assembly 
accepted resolution 63.18 to identify viral hepatitis as a 
worldwide health issue in 2010 [5,6,19]. In answer to 
this, the WHO established a 4-point plan directed at 
mobilizing resources, increasing awareness, policy, 
stopping the spread, diagnosing and treatment [6,20]. 
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In 2011, 184 nations worldwide adopted HBV in their 
vaccination program and the global coverage rate 
reached eighty percent [6,20]. At the close of 2014, the 
infants HBV vaccine had been introduced in 184 
nations worldwide [21] with a worldwide HBV 
vaccination coverage is projected at 82% while an 
increase of HBV (92%) was observed in Western 
Pacific it is as high as 92% [21]. Though 184 Nations 
integrated HBV vaccination in their immunization 
program with 82% coverage, differences persist amid 
developing and developed nations [6, 20- 21]. 
While an inexpensive and extremely effective 
recombinant DNA vaccine for HBV has existed since 
1982, it was introduced in Nigeria in 1995 [6]. In 2004, 
The Nigeria Government added HBV vaccine into the 
NPI in a bid to control HBV [4]. Though childhood 
vaccination against HBV began in Nigeria a few years 
back, and the coverage was 41% [5]. Inappropriately, 
immunization agendas in Nigeria lack sufficient funding 
or attention by the government [6]. Furthermore, 
misconceptions by the community have delayed 
cumulative coverage rates [6, 22-23].  
According to the WHO and UNICEF, HBV vaccine 
coverage was reported zero percent in 2000-2005, 
eighteen percent in 2006, and steady at forty-one 
percent in 2013 i.e. only 41% of Nigerian populace 
were vaccinated against HBV in 2013 [6, 24]. 
Odusanya [5] also noted a 58% HBV vaccine coverage 
and 80% HBV vaccine efficacy in a privately financed 
community centred vaccination scheme. Though most 
lately stated coverage rate is not significant by the 
global average, the influence can be seen with a quick 
drop in the prevalence of HBV [6]. 
HBV vaccines have an exceptional record of 
protection and efficiency [4, 25-26]. The integration of 
HBV vaccination in NPI in many countries is definitely a 
significant move to decrease the occurrence of HBV 
infection [2, 27-28]. The authors [2, 27-28] showed that 
HBsAg prevalence fell from 10.5% to 1.7% and the 
HBV prevalence decreased significantly from 25% to 
4.3% ten years after the implementation of national 
HBV inoculation plan in schools. Additionally, the 
occurrence of HCC/100000 children dropped from 0.54 
- 0.20 in children delivered prior HBV inoculation and 
after [2, 27-28]. 
HBsAg remained the main structural polypeptide 
envelope of HBV and is contained primarily of the type-
specific determinant “a” and the type-specific 
determinants “d” and “y”, found solely on the specific 
serotypes. A robust immunological reaction grows upon 
infection initially, against the type-specific determinants 
and subsequently, against the “a” determinant. Anti “a” 
antibodies are nevertheless documented to be utmost 
active in the neutralization of HBV, shielding the 
infected person from other opportunistic infections and 
causing it to convalescence. HBsAb detection has to 
turn out to be significant for the follow-up of HBV-
infected persons and the recipients monitoring upon 
inoculation with synthetic and natural HBsAg.  
Thus, this study was designed to ascertain anti-
HBsAb seroprevalence in a representative population 
of Ozuoba in Rivers State, Nigeria following the 
incorporation of HBV vaccine into NPI schedule.  
2. METHODS 
2.1. Study Area and Population 
This study was done using a representative sample 
of Ozuoba Community. The sample size was 
determined according to Macfarlane [29] and Naing et 
al. [30] equations. Therefore, the assessed sample size 
was 84 with extra 10% samples to cater for data 
inconsistencies [29-31], providing a total sample size of 
approximately 90 samples. Methods were in agreement 
with the Declaration of Helsinki (October 2008 revision) 
and the research ethics standards of the Nigerian 
National Code for Health Research Ethics. 
2.2. Sample Collection and Preparations 
A total of ninety (90) samples was collected from a 
male and female population of Ozuoba community in 
Rivers State, Nigeria. Their demographic profile (age, 
and sex) was obtained using a questionnaire. A 3 mL 
blood samples were collected from these participants 
into plain containers with no anticoagulant. Samples 
were conveyed in an ice-box to the Medical 
Microbiology Laboratory, Department of Microbiology, 
University of Port Harcourt, Nigeria. Samples were 
centrifuged and sera were extracted into Eppendorf 
tubes and stored at -20OC. 
2.3. Serological Analysis 
The serological analysis of the representative 
population of Ozuoba in Rivers State, Nigeria for anti-
HBsAb antibodies was done using ELISA (DIA.PRO 
Diagnostic Bioprobes, Milano-Italy). The serological 
evaluation and result interpretation were carried out as 
stipulated by the kit’s manufacturers.  
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2.4. Data Analysis 
Results were presented in proportions. We engaged 
Chi-square test and Fisher's exact test to ascertain 
variances amid groups at p < 0.05 significance.  
3. RESULTS 
Nine of the 90 participants evaluated were anti-
HBsAb positive giving a 10.0% general prevalence and 
a seronegativity of 90.0%. Figure 1 shows the sex-
related prevalence of HBsAb in Ozuoba, Rivers State, 
Nigeria. The sex-related prevalence was males (7.1%) 
and females (12.5%). Sex was not a predictor of 
hepatitis B surface antibody (p-value >0.05).  
 
Figure 1: Sex-related prevalence of HBsAb in Ozuoba, 
Rivers State, Nigeria. 
Figure 2 shows the age-related prevalence of 
HBsAb in Ozuoba, Rivers State, Nigeria. The age-
specific prevalence was 7.7% for age group below 20 
years, 10.2% for 20-35 years of age and 10.7% for 36 
years and above. Age was not a predictor of hepatitis B 
surface antibody (p-value >0.05).  
 
Figure 2: Age-related prevalence of HBsAb in Ozuoba, 
Rivers State, Nigeria. 
4. DISCUSSION 
Chronic HBV prevalence differs significantly in 
different parts of the World. Clearance of HBV is 
characteristically by anti-HBsAb occurrence 
homologous to HBsAg, which comprises a number of 
vital antigenic epitopes, in specific the “a” determinant 
that extends 124-147 amino-acids inside its main 
hydrophilic area [32-34]. Therefore, anti-HBsAb and 
HBsAg are characteristically not identified concurrently 
in infected persons’ sera with current infection in 
routine clinical practice [34]. But, long-lasting HBV 
infection and replication is capable occurring 
notwithstanding the existence of usually termed 
“protective” anti-HBsAb in sera of seropositive persons 
[34]. The concomitant finding of anti-HBsAb and 
HBsAg may be connected to the appearance of HBsAg 
HBV mutants in infected persons [34-36]. Persons with 
persisted positivity to HBsAg for at minimum 6 months 
are considered to be HBV carriers [37].  
Detection of antibody to the surface antigen 
(HBsAb) is generally assumed to depict immunity to 
HBV infection or HBV vaccination [38]. Anti-HBs could 
be formed in reaction to inoculation or salvage from 
HBV acute infection [38]. Chernesky et al. [39] revealed 
in their study that a significant association of HBsAb 
prevalence among anaesthetists with a history of 
previous HBV infection. It has been reported that 
regions where HBV is endemic shows high positivity for 
anti-HBs [39]. According to Chernesky et al. [39], 
country of origin might have stood as a defining factor 
to HBsAb prevalence as highest prevalence has been 
described in participants from Africa, Asia and Eastern 
Europe. Nevertheless, in other related studies amongst 
the general population, pregnant women and blood 
donors point to about 18-20% prevalence of anti-
HBsAb [40-41]. 
This study was designed to ascertain the 
prevalence of anti-HBsAb in a representative 
population of Ozuoba, Rivers State, Nigeria and such 
9(10.0%) of the 90 participants screened had anti-
HBsAb. This study in line with other studies considered 
positivity to anti-HBs only as immunity marker owing to 
HBV infection or HBV vaccination. In an earlier study, 
Lewis et al. [42] reported HBV antibody to be double as 
recurrent among healthcare workers (HCWs), 
signifying increased contact to HBV in addition that it is 
connected with the previous infection among HCWs, 
thus, signifying that obvious HBV infection is increased 
amongst HCWs.  
The 10.0% HBsAb prevalence in this study 
compared favourably to the 8.5% HBsAb prevalence 
stated by Bolarinwa et al. [38] in Ile-Ife, Osun State, 
Nigeria and the 11.7% prevalence for anti-HBs 
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reported by Janzen et al. [43]. However, the anti-
HBsAb prevalence in this representative population of 
Ozuoba is higher than 3.7% and 5.6% by Chernesky et 
al. [39] among volunteer blood donors and patients 
respectively. This is higher than the 6.9% anti-HBs 
prevalence indicated by Salpini et al. [44] in 
immunosuppressed patients. A study conducted by 
Singal et al. [45] presented a comparable prevalence of 
anti-HBsAb amid the unvaccinated and vaccinated 
groups.  
The 10.0% prevalence of anti-HBs reported in this 
study differs from what was previously reported by 
other authors in various places. In a study by 
Papaevangelou et al. [46], the prevalence of HBsAb 
was 56.7% among prostitutes. Payne et al. [47] 
reported the incidence of HBsAb in patients to be 
0.271% and 0.103% in donors. Leers [48] in a study 
among hospital staff population in Canada reported the 
prevalence of Anti-HBs to be 8.1% among North 
American staff members, 42.3% among Asians, 6.1% 
among low-risk administrative staff, 29.6% among low-
risk dietary staff and hospital assistants (30.6%). Lauer 
et al. [49] stated the anti-HBsAb seropositivity to be 
68.4% among HCWs in Turkey. Werner and Grady [50] 
reported 36.6% anti-HBsAb positivity rate among 
HCWs in South Africa. Chernesky et al. [39] reported 
16.9% prevalence in a group of anaesthetists. Romieu 
et al. [51] in their study found HBsAb seropositivity to 
be 79.2% among hospital staff . Zarina et al. [52] 
reported 46.6% for anti-HBsAb in in Dental Clinics in 
Rawalpindi/Islamabad. Zarina et al. [52] also reported 
anti-HBsAb in 26.6% lacking previous vaccination 
history against HBV in in Dental Clinics in 
Rawalpindi/Islamabad which indicated HBV sub-clinical 
infection and confirmed protection against HBV re-
infection.  
The seroprevalence rates of anti-HBs in Ozuoba, 
Rivers State, Nigeria were not similar to the prevalence 
rates in different studies conducted in recent time. 
Biswas et al. [41] in their study found anti-HBs 
seropositivity to be 48.0% in India. Zhang et al. [53] 
reported the prevalence of anti-HBsAb to be 35.66% in 
an adult populace in Ji Lin, China. Liang et al. [54] 
reported a weighted anti-HBsAb incidence for Chinese 
populace ages 1–59 years to be 50.1%. Aghakhani et 
al. [55] stated the anti-HBsAb seroprotection rate to be 
60.0%. It is also lower than 30.1% incidence of anti-
HBs reported by Biswas et al. [3] in a tertiary care 
hospital in Bangladesh. The wide range in the 
prevalence of patients with chronic HBV in different 
parts of the world is largely related to differences in the 
age at infection, which is inversely related to the risk of 
chronicity [12]. This difference is most likely attributable 
to the increase in immunization coverage ratios after 
1982 when HBV vaccine was introduced in the NPI [6].  
The sex-related prevalence was males (7.1%) and 
females (12.5%). Sex was not a predictor of hepatitis B 
surface antibody (p-value >0.05). This deviates from 
Janzen et al. [43] who reported sex to be significantly 
associated with higher rate of HBV infection than a 
control group with less exposure to infectious materials. 
Biswas et al. [41] also reported that women of 
reproductive age had a 46.7% HBsAb protective rate, 
hitherto indication of interaction with HBV was 
considerably higher with 88.3% HBcAb seropositivity. 
Zhang et al. [53] indicated male gender as an 
independent predictor of immunity to by HBV exposure. 
Our finding also corroborates that of Aghakhani et al. 
[55] who reported insignificant sex variance in anti-
HBsAb positivity. The slight difference between male 
and females in this study may be due to random errors 
during the selection of samples [56]. This slight sex-
related difference may have existed owing to the fact 
that females receive vaccination readily than males. 
Genetics, the better health-seeking behaviour may also 
be one of the predisposing factors.  
The age-specific prevalence was 7.7% for age 
group below 20 years, 10.2% for 20-35 years of age 
and 10.7% for 36 years and above. Age was not a 
predictor of anti-hepatitis B surface antibody (p-value 
>0.05). This also deviates from Janzen et al. [43] who 
reported significant age-associated HBV prevalence. 
The prevalence of HBAb was clearly age-dependent in 
the study by Papaevangelou et al. [46] contrary to the 
present findings. Zhang et al. [53] indicated older age 
as an independent predictor of immunity to by HBV 
exposure and younger age as an independent predictor 
of immunity to HBV by vaccination. The slight 
difference in age-specific prevalence between our 
study and other studies may be related to the time HBV 
vaccine was implemented in these countries. In 2015, 
Nigeria, where the vaccination programs have not 
received adequate attention or funding by the 
government until now, Musa et al. [6] reported that the 
prevalence of HBsAg in that country was 11.5% in 
children. 
Furthermore, most of the subjects used in this study 
may have been born before the introduction of HBV 
vaccine into the NPI in 2004 [6]. While most recently 
reported coverage level is low by the worldwide 
average, the impact can be magnified with a rapid 
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reduction in HBV prevalence [6]. Therefore, 
incremental efforts and even small-scale efforts aimed 
at HBV prevention and control are likely to have a great 
benefit [6]. 
This study has shown that the prevalence of HBsAb 
was low (10.0%). Our findings indicated that 
prevalence of anti-HBsAb has an insignificant 
association with age and sex. It further showed that 
90.0% were anti-HBsAb seronegative and hence, more 
susceptible to HBV infection [3]. Vaccination 
programme should be further reinforced to grasp those 
still at highest risk [54]. Thus, it should be envisaged 
that proper implementation of interventions such as 
early immunization and screening of high-risk groups 
could further reduce HBV burden as well as improve 
Nigeria's socioeconomic indices. 
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